Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker TEVA
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Mark Sabag See "Remarks" | TEVA Teva Pharmaceutical Industries Limited | Sale | 44,710 | $44.14 | $2.0M Sale | Form 4 ↗ |
| Nov 11, 2026 | Richard Daniell EVP, Europe Commercial | TEVA Teva Pharmaceutical Industries Limited | Sale | 20,003 | $42.80 | $856.2K Sale | Form 4 ↗ |
| Nov 10, 2026 | Richard D. Francis President and CEO | TEVA Teva Pharmaceutical Industries Limited | Sale | 250,000 | $42.24 | $10.6M Sale | Form 4 ↗ |
| Nov 9, 2026 | Richard Daniell EVP, Europe Commercial | TEVA Teva Pharmaceutical Industries Limited | Sale | 25,000 | $42.91 | $1.1M Sale | Form 4 ↗ |
| Nov 9, 2026 | Amir Weiss Chief Accounting Officer | TEVA Teva Pharmaceutical Industries Limited | Sale | 9,534 | $43.03 | $410.2K Sale | Form 4 ↗ |
| Nov 9, 2026 | Amir Weiss Chief Accounting Officer | TEVA Teva Pharmaceutical Industries Limited | Sale | 7,093 | $43.03 | $305.2K Sale | Form 4 ↗ |
| Nov 9, 2026 | Amir Weiss Chief Accounting Officer | TEVA Teva Pharmaceutical Industries Limited | Sale | 662 | $43.15 | $28.6K Sale | Form 4 ↗ |
| Nov 5, 2026 | Mark Sabag See "Remarks" | TEVA Teva Pharmaceutical Industries Limited | Sale | 46,000 | $41.93 | $1.9M Sale | Form 4 ↗ |
| Nov 4, 2026 | Dov Bergwerk Interim Cheif Legal Officer | TEVA Teva Pharmaceutical Industries Limited | Sale | 8,755 | $41.72 | $365.3K Sale | Form 4 ↗ |
| Nov 4, 2026 | Dov Bergwerk Interim Cheif Legal Officer | TEVA Teva Pharmaceutical Industries Limited | Sale | 17,505 | $41.72 | $730.3K Sale | Form 4 ↗ |
| Sep 18, 2026 | Brian Savage Interim Chief Legal Officer | TEVA Teva Pharmaceutical Industries Limited | Sale | 314 | $38.70 | $12.2K Sale | Form 4 ↗ |
| Sep 18, 2026 | Brian Savage Interim Chief Legal Officer | TEVA Teva Pharmaceutical Industries Limited | Sale | 2,525 | $39.15 | $98.9K Sale | Form 4 ↗ |
| Sep 18, 2026 | Brian Savage Interim Chief Legal Officer | TEVA Teva Pharmaceutical Industries Limited | Sale | 4,503 | $38.69 | $174.2K Sale | Form 4 ↗ |
| Sep 18, 2026 | Roberto Mignone Director | TEVA Teva Pharmaceutical Industries Limited | Sale | 367,600 | $39.06 | $14.4M Sale | Form 4 ↗ |
| Aug 21, 2026 | Amir Weiss Chief Accounting Officer | TEVA Teva Pharmaceutical Industries Limited | Sale | 2,500 | $37.63 | $94.1K Sale | Form 4 ↗ |
| Aug 21, 2026 | Amir Weiss Chief Accounting Officer | TEVA Teva Pharmaceutical Industries Limited | Sale | 6,945 | $37.61 | $261.2K Sale | Form 4 ↗ |
| Aug 21, 2026 | Ronit Satchi-Fainaro Director | TEVA Teva Pharmaceutical Industries Limited | Sale | 415 | $37.25 | $15.5K Sale | Form 4 ↗ |
| Aug 17, 2026 | Evan Lippman EVP, Business Development | TEVA Teva Pharmaceutical Industries Limited | Sale | 18,600 | $36.57 | $680.2K Sale | Form 4 ↗ |
| Aug 5, 2026 | Tal Zvi Zaks Director | TEVA Teva Pharmaceutical Industries Limited | Sale | 17 | $34.87 | $593 Sale | Form 4 ↗ |
| Aug 3, 2026 | Placid Jover See "Remarks" | TEVA Teva Pharmaceutical Industries Limited | Sale | 12,827 | $34.88 | $447.4K Sale | Form 4 ↗ |
| Aug 3, 2026 | Eric A. Hughes See "Remarks" | TEVA Teva Pharmaceutical Industries Limited | Sale | 25,578 | $34.88 | $892.2K Sale | Form 4 ↗ |
| Jun 18, 2026 | Matthew Shields EVP, Global Operations | TEVA Teva Pharmaceutical Industries Limited | Sale | 9,989 | $32.19 | $321.5K Sale | Form 4 ↗ |
| Jun 11, 2026 | Eliyahu Sharon Kalif EVP, Chief Financial Officer | TEVA Teva Pharmaceutical Industries Limited | Sale | 106,563 | $34.10 | $3.6M Sale | Form 4 ↗ |
| Jun 5, 2026 | Richard D. Francis President and CEO | TEVA Teva Pharmaceutical Industries Limited | Sale | 6,153 | $34.35 | $211.4K Sale | Form 4 ↗ |
| Jun 3, 2026 | Matthew Shields EVP, Global Operations | TEVA Teva Pharmaceutical Industries Limited | Sale | 16,195 | $32.87 | $532.3K Sale | Form 4 ↗ |
| May 14, 2026 | Evan Lippman EVP, Business Development | TEVA Teva Pharmaceutical Industries Limited | Sale | 35,912 | $35.58 | $1.3M Sale | Form 4 ↗ |
| May 14, 2026 | Evan Lippman EVP, Business Development | TEVA Teva Pharmaceutical Industries Limited | Sale | 5,746 | $35.58 | $204.4K Sale | Form 4 ↗ |
| May 14, 2026 | Eliyahu Sharon Kalif EVP, Chief Financial Officer | TEVA Teva Pharmaceutical Industries Limited | Sale | 153,251 | $35.61 | $5.5M Sale | Form 4 ↗ |
| May 6, 2026 | Amir Weiss Chief Accounting Officer | TEVA Teva Pharmaceutical Industries Limited | Sale | 10,679 | $36.00 | $384.4K Sale | Form 4 ↗ |
| May 5, 2026 | Richard Daniell EVP, Europe Commercial | TEVA Teva Pharmaceutical Industries Limited | Sale | 30,000 | $35.40 | $1.1M Sale | Form 4 ↗ |
| May 1, 2026 | Mark Sabag See "Remarks" | TEVA Teva Pharmaceutical Industries Limited | Sale | 144,180 | $34.99 | $5.0M Sale | Form 4 ↗ |
| Apr 30, 2026 | Christine Fox EVP, U.S. Commercial | TEVA Teva Pharmaceutical Industries Limited | Sale | 21,258 | $35.31 | $750.6K Sale | Form 4 ↗ |
| Mar 17, 2026 | Mark Sabag See "Remarks" | TEVA Teva Pharmaceutical Industries Limited | Sale | 62,102 | $30.14 | $1.9M Sale | Form 4 ↗ |
| Mar 5, 2026 | Richard D. Francis President and CEO | TEVA Teva Pharmaceutical Industries Limited | Sale | 20,025 | $31.67 | $634.2K Sale | Form 4 ↗ |
| Mar 5, 2026 | Christine Fox EVP, U.S. Commercial | TEVA Teva Pharmaceutical Industries Limited | Sale | 7,924 | $31.67 | $251.0K Sale | Form 4 ↗ |
| Mar 5, 2026 | Eric A. Hughes See "Remarks" | TEVA Teva Pharmaceutical Industries Limited | Sale | 9,533 | $31.67 | $301.9K Sale | Form 4 ↗ |
| Mar 5, 2026 | Richard Daniell EVP, Europe Commercial | TEVA Teva Pharmaceutical Industries Limited | Sale | 17,295 | $31.67 | $547.7K Sale | Form 4 ↗ |
| Mar 5, 2026 | Placid Jover See "Remarks" | TEVA Teva Pharmaceutical Industries Limited | Sale | 14,150 | $31.67 | $448.1K Sale | Form 4 ↗ |
| Mar 5, 2026 | Brian Savage Interim Chief Legal Officer | TEVA Teva Pharmaceutical Industries Limited | Sale | 1,127 | $31.67 | $35.7K Sale | Form 4 ↗ |
| Mar 5, 2026 | Matthew Shields EVP, Global Operations | TEVA Teva Pharmaceutical Industries Limited | Sale | 17,295 | $31.67 | $547.7K Sale | Form 4 ↗ |
| Mar 4, 2026 | Richard D. Francis President and CEO | TEVA Teva Pharmaceutical Industries Limited | Sale | 23,393 | $32.46 | $759.3K Sale | Form 4 ↗ |
| Mar 4, 2026 | Richard Daniell EVP, Europe Commercial | TEVA Teva Pharmaceutical Industries Limited | Sale | 37,372 | $32.95 | $1.2M Sale | Form 4 ↗ |
| Mar 4, 2026 | Richard Daniell EVP, Europe Commercial | TEVA Teva Pharmaceutical Industries Limited | Sale | 20,461 | $32.46 | $664.2K Sale | Form 4 ↗ |
| Mar 4, 2026 | Richard Daniell EVP, Europe Commercial | TEVA Teva Pharmaceutical Industries Limited | Sale | 33,512 | $32.46 | $1.1M Sale | Form 4 ↗ |
| Mar 4, 2026 | Eric A. Hughes See "Remarks" | TEVA Teva Pharmaceutical Industries Limited | Sale | 11,277 | $32.46 | $366.1K Sale | Form 4 ↗ |
| Mar 4, 2026 | Christine Fox EVP, U.S. Commercial | TEVA Teva Pharmaceutical Industries Limited | Sale | 9,098 | $32.46 | $295.3K Sale | Form 4 ↗ |
| Mar 4, 2026 | Brian Savage Interim Chief Legal Officer | TEVA Teva Pharmaceutical Industries Limited | Sale | 1,186 | $32.46 | $38.5K Sale | Form 4 ↗ |
| Mar 4, 2026 | Brian Savage Interim Chief Legal Officer | TEVA Teva Pharmaceutical Industries Limited | Sale | 1,489 | $32.46 | $48.3K Sale | Form 4 ↗ |
| Mar 3, 2026 | Richard Daniell EVP, Europe Commercial | TEVA Teva Pharmaceutical Industries Limited | Sale | 66,735 | $32.36 | $2.2M Sale | Form 4 ↗ |
| Mar 3, 2026 | Richard Daniell EVP, Europe Commercial | TEVA Teva Pharmaceutical Industries Limited | Sale | 62,250 | $32.36 | $2.0M Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 7:05 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances